請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70993
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊長豪(Chang-Hao Yang) | |
dc.contributor.author | Ying-Jung Hsu | en |
dc.contributor.author | 許穎絨 | zh_TW |
dc.date.accessioned | 2021-06-17T04:47:27Z | - |
dc.date.available | 2021-02-23 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-17 | |
dc.identifier.citation | Abke S.; Neumeier M.; Weigert J.; Wehrwein G.; Eggenhofer E.; Schäffler A.; Maier K.; Aslanidis C.; Schölmerich J.; Buechler C. (2006) “Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) is impaired in monocytes from patients with type 1 diabetes.” Cardiovasc Diabetol 5:17.
Adams J. M. and Cory S. (1998) “The Bcl-2 protein family: Arbiters of cell survival.” Science 281(5381):1322–1326. Amadio M.; Bucolo C.; Leggio G. M.; Drago F.; Govoni S.; Pascale A. (2010) “The PKCbeta /HuR /VEGF pathway in diabetic retinopathy.” Biochem Pharmacol 80(8):1230–1237. Anderson R. E.; Rapp L. M.; Wiegand R. D. (1984) “Lipid peroxidation and retinal degeneration.” Curr Eye Res 3(1):223-7. Arora M. K.; Reddy K.; Balakumar P. (2010) “The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.” Eur J Pharmacol 636(1-3):137-44. Baraka A. and AbdelGawad H. (2010) ” Targeting apoptosis in the heart of Streptozotocin-induced diabetic rats.” J Cardiovasc Pharmacol Ther 15(2): 175-81. Barb D.; Williams C. J.; Neuwirth A. K.; Mantzoros C. S. (2007) “Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.” Am J Clin Nutr 86(3):S858-66. Bergamini C. M.; Gambetti S.; Dondi A.; Cervellati C. (2004) “Oxygen, reactive oxygen species and tissue damage.” Curr Pharm Des 10(14):1611-26. Besson V. C.; Chen X. R.; Plotkine M.; Marchand-Verrecchia C. (2005) “Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.” Neurosci Lett 388(1):7-12. Billiet L.; Furman C.; Cuaz-Perolin C.; Paumelle R.; Raymondjean M.; Simmet T.; Rouis M. (2008) “Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages.” J Mol Biol 384(3):564-576. Bogdanov P.; Hernandez C.; Corraliza L.; Carvalho A.R.; Simo R. (2015) “Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes.” Acta Diabetol 52(1):113-122. Bordet R.; Ouk T.; Petrault O.; Gele P.; Gautier S.; Laprais M.; Deplanque D.; Duriez P.; Staels B.; Fruchart J.C.; Bastide M. (2006) “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.” Biochem Soc Trans 34(Pt 6):1341-1346. Boyer D. S.; Yoon Y.H.; Belfort R. Jr.; Bandello F.; Maturi R. K.; Augustin A. J.; Li X. Y.; Cui H.; Hashad Y.; Whitcup S. M.; Ozurdex MEAD Study Group. (2014) “Three-year,randomized, shame-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edama.” Ophthalmology 121(10):1904-14. Browning D. J.; Stewart M. W.; Lee C. (2018) “Diabetic macular edema: evidence-based management.” Indian J Ophthalmol 66(12):1736-1750. Brownlee M. (2005) “The pathobiology of diabetic complications: a unifying mechanism.” Diabetes 54(6):1615-1625. Buse M. G. (2006) “Hexosamines, insulin resistance, and the complications of diabetes: current status.” Am J Physiol Endocrinol Metab 290(1):E1-E8. Cai Y.; Li W.; Tu H.; Chen N.; Zhong Z.; Yan P.; Dong J. (2017) “Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.” 27(8):1835-1839. Castillero E.; Martin A. I.; Nieto-Bona M. P.; Fernández-Galaz C.; López-Menduiña M.; Villanúa M. Á.; López-Calderón A. (2012) “Fenofibrate administration to arthritic rats increases adiponectin and leptin and prevents oxidative muscle wasting.” Endocr Connect 1(1):1-12. Chen J. T.; Chen L. J.; Chen S. N.; Chen W. L.; Cheng C.K.; Hsu S. M.; Sheu S. J.; Wu W. C.; Yang C. H.; Yang C. M.; Yeung L.; Hwang D. K.; Chen S. J. (2020) “Management of diabetic macular edema: expert’s consensus in Taiwan.” Japan J Ophthalmol 64:235-242. Chen Y.; Hu Y.; Lin M.; Jenkins A. J.; Keech A. C.; Mott R.; Lyons T. J.; Ma J. X. (2013) “Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models.” Diabetes 62(1):261-272. Chew E. Y.; Ambrosius W. T.; Davis M. D.; Danis R. P.; Gangaputra S.; Greven C. M.; Hubbard L.; Esser B. A.; Lovato J. F.; Perdue L. H.; Goff D. C. Jr.; Cushman W. C.; Ginsberg H. N.; Elam M. B.; Genuth S.; Gerstein H. C.; Schubart U.; Fine L. J. (2010) “Effects of medical therapies on retinopathy progression in type 2 diabetes.” N Engl J Med 363(3):233-244. Chinetti G.; Zawadski C.; Fruchart J. C.; Stael S. (2004) “Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.” Biochem Biophys Res Commun 314(1):151-8. Costagliola C.; Daniele A.; dell'Omo R.; Romano M. R.; Aceto F.; Agnifili L.; Semeraro F.; Porcellini A. (2013) “Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection.” Exp Eye Res 110:50-4. Cui Y.; Xu X.; Bi H.; Zhu Q.; Wu J.; Xia X.; Ren Q.; Ho P. (2006) “Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy.” Exp Eye Res 83(4):807-16. Das Evcimen N.; King G. L. (2007) “The role of protein kinase C activation and the vascular complications of diabetes.” Pharmacol Res 55(6):498–510. Devi T. S.; Hosoya K.; Terasaki T.; Singh L.P. (2013) “Critical role of TXNIP in oxidative stress, DNA damage and retinal pericyte apoptosis under high glucose: implications for diabetic retinopathy.” Exp Cell Res 319(7):1001-1012. Ding L.; Cheng R.; Hu Y.; Takahashi Y.; Jenkins A. J.; Keech A. C.; Humphries K. M.; Gu X.; Elliott M. H.; Xia X.; Ma J. X. (2014) “Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina.” Am J Pathol 184:2709-2720. Doganay S.; Evereklioglu C.; Er H.; Türköz Y.; Sevinç A.; Mehmet N; Savli H. (2002) “Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.” Eye (Lond) 16(2): 163-70. Dohmen K.; Wen C. Y.; Nagaoka S.; Yano K.; Abiru S.; Ueki T,; Komori A.; Daikoku M.;Yatsuhashi H.; Ishibashi H.. (2005) “Fenofibrate-induced liver injury.” World J Gastroenterol 11(48):7002-3. Du Y.; Miller C. M.; Kern T. S. (2003) “Hyperglycemia increases mitochondrial superoxide in retina and retinal cells.” Free Radic Biol Med 35(11):1491-9. Ellis E. A.; Guberski D. L.; Somogyi-Mann M.; Grant M. B. (2000) “Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat.” 28(1):91-101. Feenstra D. J.; Yego E. C.; Mohr S. (2013) “Modes of retinal cell death in diabetic retinopathy.” J Clin Exp Ophthalmol 4(5):298. Feldman E. L. (2003) “Oxidative stress and diabetic neuropathy: a new understanding of an old problem.” J Clin Invest 111(4):431-433. Fiuza B.; Subelzu N.; Calcerrada P.; Straliotto M. R.; Piacenza L.; Cassina A.; Rocha J. B.; Radi R.; de Bem A. F.; Peluffo G. (2015) “Impact of SIN-1-derived peroxynitrite flux on endothelial cell redox homeostasis and bioenergetics: protective role of diphenyl diselenide via induction of peroxiredoxins.” Free Radic Res 49(2): 122-132. Friedlander R. M. (2003) “Apoptosis and caspases in neurodegenerative diseases.” N Engl J Med 348(14):1365-1375. Fruchart J. C. (2009) “Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.” Atherosclerosis 205(1):1-8. Fujii Y.; Okada A.; Yasui T.; Niimi K.; Hamamoto S.; Hirose M.; Kubata Y.; Tozawa K.; Hayashi Y.; Kohri K. (2013) “Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis” PLoS One 8(4):e61343. Gao M.; Bu L.,; Ma Y.; Liu D. (2013) “Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.” PLoS One 8(6):e65641. Garrido E. O. and Grant C. M. (2002) “ Role of thioredoxins in the response of Saccharomyces cerevisiae to oxidative stress induced by hydroperoxides.” Mol Microbiol 43(4):993-1003. Gendron R.; Good W. ; Adams L.; Paradis H. (2001) “Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy.” Invest Ophthalmol Vis Sci 42(12):3000-3007. Giacco F. and Brownlee M. (2010) “Oxidative stress and diabetic complications.” Circ Res 107(9):1058-1070. Grabacka M. and Reiss K. (2008) “Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation.” PPAR Res 2008:930705. Hadjadj S.; Aubert R.; Fumeron F.; Pean F.; Tichet J.; Roussel R.; Marre M. SURGENE Study Group; DESIR Study Group (2005) “Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects.” Diabetologia 48(6):1088-92. Hayakawa T.; Hayashi A.; Miyakawa M.; Shimoyama K.; Sekiya S.; Sekiguchi M.; Inotsume N. (2002) “[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].” Yakugaku Zasshi 122(2):169-75. Hernandez C.; Segura R. M.; Fonollosa A.; Carrasco E.; Francisco G.; Simó R. (2005) “Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy.” Diabet Med 22(6):719-22. Ho C. Y.; Kuo T. H.; Chen T. S.; Tsay S. H.; Chang F.Y.; Lee S.D. (2004) 'Fenofibrate-induced acute cholestatic hepatitis.' J Chin Med Assoc 67(5):245-7. Hu Y.; Chen Y.; Ding L.; He X.; Takahashi Y.; Gao Y.; Shen W.; Cheng R.; Chen Q.; Qi X.; Boulton M. E.; Ma J. X. (2013) “Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction.” Proc Natl Acad Sci USA 110(38):15401-15406. Hudson B. I.; Stickland M. H.; Futers T. S.; Grant P. J. (2001) “Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.” Diabetes 50(6):1505-11. Huh K. H.; Cho Y.; Kim B. S.; Do J. H.; Park Y. J.; Joo D. J.; Kim M. S.; Kim Y. S. (2013) “The role of thioredoxin 1 in the mycophenolic acid-induced apoptosis of insulin-producing cells.” Cell Death Dis 4(7):e721. Jenkins A. J.; Joglekar M.V.; Hardikar A. A.; Keech A.C.; O'Neal D. N.; Januszewski A. S. (2015) “Biomarkers of diabetic retinopathy.” Rev Diabet Stud 12(1-2):159-95. Jeong H. S.; Choi H. Y.; Choi T. W.; Kim B. W.; Kim J. H.; Lee E. R.; Cho S. G. (2008) “Differential regulation of the antiapoptotic action of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra long (Bcl-xL) by c-Jun N-terminal protein kinase (JNK) 1-involved pathway in neuroglioma cells.” Biol Pharm Bull 31(9):1686-1690. Kadian S.; Mahadevan N.; Balakumar P. (2013) “Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.” Eur J Pharmacol 698(1-3):388-396. Katagiri M,; Shoji J,; Inada N,; Kato S,; Kitano S,; Uchigata Y. (2018) “Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy.” Int Ophthalmol. 38(2):607-615. Kato K.; Osawa H.; Ochi M.; Kusunoki Y.; Ebisui O.; Ohno K.; Ohashi J.; Shimizu I.; Fujii Y.; Tamimoto M.; Makino H. (2008) “Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy.” Clin Endocrinol (Oxf) 68(3):442-9. Keech A. C.; Mitchell P.; Summanen P. A.; O'Day J.; Davis T. M.; Moffitt M. S.; Taskinen M. R.; Simes R. J.; Tse D.; Williamson E.; Merrifield A.; Laatikainen L. T.; d'Emden M. C.; Crimet D. C.; O'Connell R. L.; Colman P. G. (2007) “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.” Lancet 370(9600):1687-1697. Kern T. S.; Tang J.; Mizutani M.; Kowluru R. A.; Nagaraj R. H.; Romeo G.; Podesta F.; Lorenzi M. (2000) “Response of capillary cell death to aminoguanidine predicts the development of retinoparhy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41(12):3972-8. Kim J.; Ahn J. H.; Kim J. H.; Yu Y. S.; Kim H. S.; Ha J.; Shinn S. H.; Oh Y. S. (2007) “Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.” Exp Eye Res 84(5):886-93. Koh K. K.; Quon M. J.; Lim S.; Lee Y.; Sakuma I.; Lee Y. H.; Han S. H.; Shin E.K. (2011) “Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.” Atherosclerosis 214(1):144-7. Komura N.; Maeda N.; Mori T.; Kihara S.; Najatsuji H.; Hirata A.; Tochino Y.; Funahashi T.; Shimomura I. (2013) “Adiponectin protein exists in aortic endothelial cells.” PLoS One 8(8):e71271. Kowluru R.A. (2005) “Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions.” Life Sci 76(9):1051-60. Kowluru R. A. and Abbas S. N. (2003) “Diabetes-induced mitochondria dysfunction in the retina.” Invest Ophthalmol Vis Sci 44(12):5327-34. Kowluru R. A. and Koppolu P. (2002) “Termination of experimental galactocemia in rats, and progression of retinal metabolic abnormalities.” Invest Ophthalmol Vis Sci 43(10):3287-91. Kowluru R. A. and Odenbach S. (2004) “Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in dibetic rats.” Diabetes 53(12):3233-8. Kusunoki N.; Kitahara K.; Kojima F.; Tanaka N.; Kaneko K.; Endo H.; Suguro T.; Kawai S. (2010) “Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts.” Arthritis Rheum 62(6):1641-9. Li F. Y.; Cheng K. K.; Lam K. S.; Vanhoutte P. M.; Xu A. (2011) “Cross-talk between adipose tissue and vasculature: role of adiponectin.” Acta Physiol (Oxf) 203(1):167-80. Lin J. C.; Shau W. Y.; Lai M. S. (2014) “Sex- and age-specific prevalence and incidence rates of sight-threatening diabetic retinopathy in Taiwan.” JAMA Ophthalmol 132:922-8. Lin T.; Qiu Y.; Liu Y.; Mohan R.; Li Q.; Lei B. (2013) “Expression of adiponectin and its receptors in type 1 diabetes mellitus in human and mouse retinas.” Mol Vis 19:1769-78. Liu G. H.; Qu J.; Shen X. (2006) “Thioredoxin-mediated negative autoregulation of peroxisome proliferator-activated receptor alpha transcriptional activity.” Mol Biol Cell 17(4):1822-1833. Liu J.; Lu C.; Li F.; Wang H.; He L.; Hao Y.; Chen A.F.; An H.; Wang X.; Hong T.; Wang G. (2011) “PPAR-alpha agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of guanosine 5'-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells.” PPAR Res 2011:523520. Lukiw W. J.; Ottlecz A.; Lambrou G.; Grueninger M.; Finley J.; Thompson H. W.; Bazan N.G. (2003) “Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia.” Invest Ophthalmol Vis Sci 44(10):4163-4170. Madsen-Bouterse S. A.; Kowluru R. A. (2008) “Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.” Rev Endocr Metab Disord 9(4):315-327. Mahadev K.; Wu X.; Donnelly S.; Ouedraogo R.; Eckhart A. D.; Goldtein B. J. (2008) “Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells.” Cardiovasc Res 78(2):376-84. Mao D.; Peng H.; Li Q.; Wang J.; Li P.; Hu K.; Zhang X.; Lei B. (2012) “Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathy patients.” Curr Eye Res 37(9):803-8. Matsui M.; Oshima M.; Oshima H.; Takaku K.; Maruyama T.; Yodoi J.; Taketo M. M. (1996) “Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene.” Dev Biol 178(1):179-185. Miranda S.; Gonzalez-Rodriguez A.; Garcia-Ramirez M.; Revuelta-Cervantes J.; Hernandez C.; Simo R.; Valverde A.M. (2012) “Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.” J Cell Physiol 227(6):2352-2362. Murugeswari P.; Shukla D.; Kim R.; Namperumalsamy P.; Stitt A. W.; Muthukkaruppan V. (2014) “Angiogenic potential of vitreous from proliferative diabetic retinopathy and Eales’ disease patients.” PLoS One 9(10):e107551. Nakamura H.; Nakamura K.; Yodoi J. (1997) “Redox regulation of cellular activation.” Annu Rev Immunol 15:351-69. Neumeier M.; Weigert J.; Schaffler A.; Weiss T.; Kirchner S.; Laberer S.; Schölmerich J.; Buechler C. (2005) “Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.” Biochem Biophys Res Commun 334(3):924-9. Niso-Santano M.; Gonzalez-Polo R.A.; Bravo-San Pedro, J.M.; Gomez-Sanchez R.; Lastres-Becker I.; Ortiz-Ortiz M.A.; Soler G.; Moran J.M.; Cuadrado A.; Fuentes J.M. (2010) “Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis.” Free Radic Biol Med 48(10):1370-1381. Nonn L.; Williams R.R.; Erickson R.P.; Powis G. (2003) “The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice.” Mol Cell Biol 23(3):916-922. Ogata T.; Miyauchi T.; Sakai S.; Takanashi M.; Irukayamatomobe Y.; Yamaguchi I. (2004) “ Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.” J Am Coll Cardiol 43(8):1481-8. Ogurtsova K.; da Rocha Fernandes J.D.; Huang Y.; Linnenkamp U.; Guariguata L.; Cho N.H. et al. (2017) “IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040.” Diabetes Res Clin Pract 128:40-50. Okamoto Y.; Kihara S.; Ouchi N.; Nishida M.; Arita Y.; Kumada M.; Ohashi K.; Sakai N.; Shimomura I.; Kobayashi H.; Terasaka N.; Inaba T.; Funahashi T.; Matsuzawa Y. (2002) “Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.” Circulation 106(22):2767-70. Oki K.; Koide J.; Nakanishi S.; Nakashima R.; Yamane K. (2007) “Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.” Endocr J 54(3):431-5. Ouchi N.; Kobayashi H.,; Kihara S.; Kumada M.; Sato K.; Inoue T.; Funahashi T.; Walsh K. (2004) “Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells.” J Biol Chem 279(2):1304-9. Palanker D. V.; Blumenkranz M. S.; Marmor M. F. (2011) “Fifty years of ophthalmic laser therapy.” Arch Ophthalmol 129:1613-9. Park J. Y.; Ha S. W.; King G. L. (1999) “The role of protein kinase C activation in the pathogenesis of diabetic vascular complications.” Perit Dial Int 19(Supplement 2):S222–S227. Park, S.W.; Cho, C.S.; Jun, H.O.; Ryu, N.H.; Kim, J.H.; Yu, Y.S.; Kim, J.S.; Kim, J.H. (2012) “Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production.” Invest Ophthalmol Vis Sci 53(12): 7718-7726. Pearsall E. A.; Cheng R.; Matsuzaki S.; Zhou K.; Ding L.; Ahn B.; Kinter M.; Humphries K. M.; Quiambao A. B.; Farjo R. A.; Ma J. X. (2019) “Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.” PloS one 14(2):e0208399. Pedro R-A.; Marc B-B,; Alicia P-R.; Maribel L-G.; Raul N-G.; Raquel V. (2016) “Diabetic macular edema pathophysiology: vasogenic versus imflammatory.” J Diabetes Res 2016:2156273. Perri A.; Vizza D.; Lofaro D.; Gigliotti P.; Leone F.; Brunelli E.; Malivindi R.; Amicis F. D.; Romeo F.; Stefano R.D.; Papalia T.; Bonofiglio R. (2013) “Adiponectin is expressed and secreted by renal tubular epithelial cells.” J Nephrol 26(6):1049-54. Powis G.; Montfort W. R. (2001) “Properties and biological activities of thioredoxins.” Annu Rev Pharmacol Toxicol 41:261-295. Quagliaro L.; Piconi L.; Assaloni R.; Martinelli L.; Motz E.; Ceriello A. (2003) “Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation.” Diabetes 52(11):2795-2804. Rahman S. M.; Qadri I.; Janssen R. C.; Friedman J. E. (2009) “Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.” J Lipid Res 50(11): 2193-202. Rhee S.G.; Kang S.W.; Chang T.S.; Jeong W.; Kim K. (2001) “Peroxiredoxin, a novel family of peroxidases.” IUBMB Life 52(1-2):35-41. Rosenson R. S. (2008) “Fenofibrate: treatment of hyperlipidemia and beyond.” Expert Rev Cardiovasc Ther 6(10):1319-30. Rovin B. H. and Song H. (2006) “Chemokine induction by the adipocyte-derived cytokine adiponectin.”Clin Immunol 120(1):99-105. Saxena G.; Chen J.; Shalev A. (2010) “Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein.” J Biol Chem 285(6):3997-4005. Schmidt-Erfurth U.; Garcia-Arumi J.; Bandello F.; Berg K.; Chakravarthy U.; Gerendas B. S.; Janos J.; Larsen M.; Tadayoni R.; Loewenstein A. (2017) “Guidelines for the management of diabetic mocular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237(4):185-222. Schmidt R. E.; Dorsey D. A.; Beaudet L. N.; Parvin C. A.; Yarasheski K. E.; Smith S. R.; Williamson J. R.; Peterson R. G.; Oates P. J. (2005) “A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetes.” Exp Neurol 192(2):407-19 Schoonjans K.; Martin G.; Staels B.; Auwerx J. (1997) “Peroxisome proliferator-activated receptors, orphans with ligands and functions.” Curr Opin Lipidol 8(3): 159-166. Shibata R.; Ouchi N.; Kihara S.; Sato K.; Funahashi T.; Walsh K. (2004) “Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling.” J Biol Chem 279(2):28670-4. Simó-Servat O.; Hernándze C.; Simó R. (2012) “Usefulness of the vitreous fluid analysis in the translational research of diabetic research.” Mediators Inflamm 2012:872978. Singh L. P. (2013) “Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.” J Clin Exp Ophthalmol 4:10.4172/2155-9570.1000287. Sjølie A. K. and Chaturvedi N. (2002) “ The retinal renin-angiotensin system: Implications for therapy in diabetic retinopathy.” J Hum Hypertens. Suppl 3:S42-6. Staels B.; Dallongeville J.; Auwerx J.; Schoonjans K.; Leitersdorf E.; Fruchart J. C. (1998) “ Mechanism of action of fibrates on lipid and lipoprotein metablism.” Circulation 98(19):2088-93. Steven F. A. (2013) “Direct effects of PPAR-α agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.” Diabetes 62(1):36-38. Stitt A. W.; Curtis T. M.; Chen M.; Medina R. J.; McKay G. J.; Jenkins A.; Gardiner T. A.; Lyons T. J.; Hammes H. P.; Simó R.; Lois, N. (2016) “The progress in understanding and treatment of diabetic retinopathy.” Prog Retin Eye Res 51:156–186. Tan E.; Ding X. Q.; Saadi A.; Agarwal N.; Naash M.; Al-Ubaidi M. R. (2004) “Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice.” Invest Ophthalmol Vis Sci 45(3):764-8. Tan W.; Wang F.; Zhang M.; Guo D.; Zhang Q.; He S. (2009) “High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis.” Semin Arthritis Rheum 38(6):420-7. Tanaka T.; Hoso, F.; Yamaguchi-Iwai Y.; Nakamura H.; Masutani H.; Ueda S.; Nishiyama A.; Takeda S.; Wada H.; Spyrou G.; Yodoi J. (2002) “Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis.” EMBO J 21(7):1695-1703. Tang J. and Kern T. S. (2011) “Imflammation in diabetic retinopathy.” Prog Retin Eye Res 30(5):343-58. Terasaki H.; Ogura Y.; Kitano S.; Sakamoto T.; Murata T.; Hirakata A.; Ishibashi T. (2018) “Management of diabetic macular edema in Japan: a review and expert opinion.” Jpn J Ophthalmol 62(1):1-23. Tobiume K.; Matsuzawa A.; Takahashi T.; Nishitoh H.; Morita K.; Takeda K.; Minowa O.; Miyazono K.; Noda T.; Ichijo H. (2001) “ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis.” EMBO Rep 2(3):222-228. Trudeau K.; Roy S.; Guo W.; Hernandez C.; Villarroel M.; Simo R.; Roy S. (2011) “Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.” Invest Ophthalmol Vis Sci 52(9): 6348-6354. Watson W. H.; Yang X.; Choi Y. E.; Jones D. P.; Kehrer J. P. (2004) “Thioredoxin and its role in toxicology.” Toxicol Sci 78(1):3-14. Weyer C.; Funahashi T.; Tanaka S.; Hotta K.; Matsuzawa Y.; Pratley R. E.; Tataratti R. A. (2001) “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.” J Clin Endocrinol Metab 86(5):1930-5. Wilkinson-Berka J. L. and Miller A. G. (2008) “Update on the treatment of diabetic retinopathy.” Scient World J 8:98-120. Williams R.; Airey M.; Baxter H.; Forrester J.; Kennedy-Martin T.; Girach A. (2004) “Epidemiology of diabetic retinopathy and macular oedema: a systematic review.” Eye (Lord) 18(10):963-83. Wong T.Y.; Simo R.; Mitchell P. (2012) “Fenofibrate - a potential systemic treatment for diabetic retinopathy?” Am J Ophthalmol 154(1):6-12. Wu L.; Xu B.; Fan W.; Zhu X.; Wang G.; Zhang A. (2013) “Adiponectin protects Leydig cells against proinflammatory cytokines by suppressing the nuclear factor-kappaB signaling pathway.” Febs J 280(16):3920-7. Wu M. Y.; Yiang G. T.; Lai T. T.; Li C. J. (2018) “ The oxidative stress and mitochondria dysfunction during the pathogenesis of diadetic retinopathy.” Oxid Med Cell Longev 2018:3420187. Yamauchi T.; Iwabu M.; Okada-Iwabu M.; Kadowaki T. (2014) “Adiponectin receptors: a review of their structure, function and how they work.” Best Pract Res Clin Endocrinol Metab 28(1):15-23. Yamauchi T.; Kamon J.; Waki H.; Terauchi Y.; Kubota N.; Hara K.; Mori Y.; Ide T.; Murakami K.; Tsuboyama-Kasaoka N.; Ezaki O,; Akanuma Y.; Gavrilova O.; Vinson C.; Reitman M. L.; Kagechika H.; Shudo K.; Yoda M.; Nakano Y.; Tobe K.; Nagai R.; Kimura S.; Tomita M.; Froguel P.; Kadowaki T. (2001) “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.” Nat Med 7(8):941-6. Yanai H,; Yoshida H. (2018) “ Beneficial effect of adiponectin on glocuse and lipid metabolism and atherosclerotic progression: mechanisms and perspectives.” Int J Mol Sci 20(5):1190. Yang M. C.; Tan E. C.; Su Y. J.; Lai C. C. (2012) “PSS2 Epidemiology, treatment patterns and medical expenses of diabetic macular edema in Taiwan: a nationwide claim-base databases study.” Value Health 15:A642. Yang W. S.; Lee W. J.; Funahashi T.; Tanaka S.; Matsuzawa Y.; Chao C. L.; Chan C. L.; Tai T. Y.; Chuang L. M. (2001) “Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin.” J Clin Endocrinol Metab 86(8):3815-9. Yeh P. T.; Wang L. C.; Chang S.W.; Yang W.S.; Yang C.M.; Yang C.H. (2019) “Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model.” Curr Eye Res 44(10):1121‐1132. Yoneda K.; Tomimoto A.; Endo H; Iida H.; Sugiyama M.; Takahashi H.; Mawatari H.; Nozaki Y.; Fujita K.; Yoneda M.; Inamori M.; Nakajima N.; WadaK.; Nagashima Y.; Nakagama H.; Uozaki H.; Fukayama M. Nakajima A. (2008) “Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue.” Oncol Rep 20(3):479-83. You J. J.; Yang C. H.; Yang C. M.; Chen M. S. (2014) “Cyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin ανβ3, FAK, PI3K/Akt, and NF-κB pathways in retinal vascular endothelial cells.” Cell Signal 26(1):133-140. You J. J.; Yang C. M.; Chen M. S.; Yang C. H. (2010) “Regulation of Cyr61/CCN1 expression by hypoxia through cooperation of c-Jun/AP-1 and HIF-1a in retinal vascular endothelial cells.” Exp Eye Res 91(6):825-836. Yuan L.; Wang J.; Xiao H.; Wu W.; Wang Y.; Liu X. (2013) “MAPK signaling pathways regulate mitochondrial-mediated apoptosis induced by isoorientin in human hepatoblastoma cancer cells.” Food Chem Toxicol 53:62-68. Zhang R.; Al-Lamki R.; Bai L.; Streb J. W.; Miano J. M.; Bradley J.; Min W. (2004) “Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner.” Circ Res 94(11):1483-1491. Zhang W.; Liu H.; Al-Shabrawey M.; Caldwell R. W.; Caldwell R. B. (2011) “Inflammation and diabetic retinal microvascular complications.” J Cardiovasc Dis Res 2(2):96-103. Zhang X.; Fu Y.; Xu X.; Li M.; Du L.; Han Y.; Ge Y. (2014) “PERK pathway are involved in NO-induced apoptosis in endothelial cells cocultured with RPE under high glucose conditions.” Nitric Oxide 40:10-16. Zhu W.; Cheng K. K.; Vanhoutte P. M.; Lam K. S. L.; Xu A. (2008) “Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention.” Clin Sci (Lond) 114(5):361-74. Zietz B.; Buechler C.; Kobuch K.; Neumeier M.; Schölmerich J.; Schäffler A. (2008) “Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2.” Exp Clin Endocrinol Diabetes 116(9):532-6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70993 | - |
dc.description.abstract | 糖尿病視網膜病變是一種重要的糖尿病微血管併發症,也是在已開發國家中造成失明的主因之一。有大型臨床研究文獻指出降血脂藥物fenofibrate 為一種 peroxisome proliferator-activated receptor-α促效劑並且具有阻止糖尿病視網膜病變病程的潛能。我們的研究包含兩大部分,第一部分是fenofibrate對於氧化壓力所引起視網膜/脈絡膜血管內皮細胞凋亡之保護作用。我們評估RF/6A 細胞在受到paraquat所引發氧化壓力情況下fenofibrate 的保護作用並研究潛在的機制。相較於paraquat刺激的細胞,預先經過fenofibrate 處理可抑制自由基的產生,降低細胞凋亡比例並且減少粒線體膜電位的改變。Fenofibrate 會使peroxiredoxin (Prx)、thioredoxins (Trxs)、B-cell lymphoma 2 (Bcl-2)及Bcl-xl 的 mRNA 增加,並降低B-cell lymphoma 2-associated X protein (Bax) 的mRNA。西方點墨法結果顯示fenofibrate 減少細胞凋亡反應是透過細胞質及粒線體的apoptosis signal-regulated kinase-1 (Ask)-Trx相關訊息傳導路徑,包括c-Jun amino-terminal kinase (JNK) 磷酸化,cytochrome c 由粒線體釋出,caspase 3活化,以及 poly (ADP-ribose) polymerase (PARP) 裂解。這些保護作用也許可歸因於fenofibrate 在RF/6A 細胞的抗氧化能力。此研究顯示fenofibrate 也許能在氧化壓力相關的眼科疾病中提供有效的附屬治療。第二部份是fenofibrate對於第一型糖尿病大鼠視網膜內脂聯素表現之影響。脂聯素是一種特殊脂肪細胞蛋白,並與增加糖尿病微血管併發症的風險有相關性。然而,目前仍不清楚脂聯素在糖尿病視網膜病變中所扮演的角色。在此研究中,我們研究脂聯素及其受體在糖尿病大鼠中的表現,以及評估在動物體及細胞中 fenofibrate 對脂聯素及其受體表現之影響。在糖尿病大鼠視網膜中,脂聯素及其受體的mRNA 和蛋白質表現量會增加,但經過fenofibrate 治療的大鼠其視網膜中脂聯素及其受體的mRNA 和蛋白質表現量會受到抑制。免疫螢光染色結果顯示脂聯素及受體1表現於血管內、 視網膜神經節以及內核層。脂聯素受體1 也強烈表現於血管內皮細胞,反之受體 2 只有少量表現於血管內皮細胞。在細胞實驗中,RGC-5細胞及RAW264.7細胞受高糖濃度刺激下脂聯素的表現量會上升,但預先經過fenofibrate 處理之細胞其脂聯素表現會受到抑制。脂聯素受體1及受體2 在RGC-5 細胞受高糖濃度刺激下表現量會上升,但預先經過fenofibrate 處理之細胞其受體表現會受到抑制。以上結果顯示脂聯素在糖尿病視網膜中可能是一種發炎反應前的中介物並在病程中扮演重要角色。Fenofibrate 在糖尿病視網膜中可能透過調節脂聯素及其受體的表現進而有效減緩糖尿病視網膜病變之病程。 | zh_TW |
dc.description.abstract | Diabetic retinopathy (DR) is an important microvascular complication of diabetes and one of the leading causes of blindness in developed countries. Two large clinical studies showed that fenofibrate is a peroxisome proliferator-activated receptor-αagonist that has been shown to be capable of preventing DR progression. Our research comprehends two parts. The first part demonstrated that the effect of fenofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells. We evaluated the protective effects of fenofibrate on retinal/choroidal vascular endothelial cells under oxidative stress and investigated the underlying mechanisms using RF/6A cells as the model system and paraquat (PQ) to induce oxidative stress. Pretreatment with fenofibrate suppressed reactive oxygen species (ROS) production, decreased cellular apoptosis, diminished the changes in the mitochondrial membrane potential, increased the mRNA levels of peroxiredoxin (Prx), thioredoxins (Trxs), B-cell lymphoma 2 (Bcl-2), and Bcl-xl, and reduced the level of B-cell lymphoma 2-associated X protein (Bax) in PQ-stimulated RF/6A cells. Western blot analysis revealed that fenofibrate repressed apoptosis through cytosolic and mitochondrial apoptosis signal-regulated kinase-1 (Ask)-Trx-related signaling pathways, including c-Jun amino-terminal kinase (JNK) phosphorylation, cytochrome c release, caspase 3 activation, and poly (ADP-ribose) polymerase (PARP) cleavage. These protective effects of fenofibrate on RF/6A cells may be attributable to its anti-oxidative ability. Our research suggests that fenofibrate could serve as an effective adjunct therapy for ocular oxidative stress-related disorders, such as DR. The second part demonstrated that the effect of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats. Adiponectin is an adipocyte-specific protein that has been associated with increased risks of microvascular complications in diabetes; however, its role in the development of DR is largely unknown. In this study, we investigated the expression of adiponectin and its receptors in DR and evaluated the effects of fenofibrate on their expression in vivo and in vitro. The mRNA and protein levels of adiponectin and its receptors were elevated in retinas of streptozotocin-induced diabetic rats and were suppressed following fenofibrate treatment. Immunofluorescence staining demonstrated that adiponectin and adipoR1 were expressed in cells located within blood vessels, the retinal ganglion, and the inner nuclear layer. AdipoR1 was also strongly expressed in vascular endothelial cells, whereas adipoR2 was only expressed at low levels in vascular endothelial cells. The in vitro experiments showed that adiponectin expression was induced by high glucose concentrations in RGC-5 and RAW264.7 cells and was suppressed following fenofibrate treatment. AdipoR1 and adipoR2 levels in RGC-5 cells were elevated following exposure to high glucose concentrations and suppressed after fenofibrate treatment. Our results demonstrated that adiponectin may be a pro-inflammatory mediator in diabetic retinas and play an important role in the development of DR. Fenofibrate appears to modulate the expression of adiponectin and its receptors in diabetic retinas, effectively reducing DR progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:47:27Z (GMT). No. of bitstreams: 1 U0001-1702202112194900.pdf: 2812726 bytes, checksum: d7178f44ed33a0eb244a221c9f9ffdd9 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | Contents 口試委員會審定書..................................................................i 誌謝............................................................................ii 中文摘要........................................................................iii Abstract.........................................................................v Figure Contents.................................................................xi Table Contents.................................................................xiv Chapter 1. Introduction..........................................................1 1.1 Introduction of diabetic retinopathy.....................................1 1.2 The role of oxidative stress in the diabetic retinopathy pathogenesis....2 1.3 Introduction of fenofibrate..............................................6 1.4 Introduction of thioredoxin..............................................9 1.5 Introduction of adiponectin.............................................10 1.6 The purposes of our research............................................11 Chapter 2. Materials and Methods................................................14 2.1 Protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells.............................14 2.2 Effect of fenofibrate on adiponectin expression in retinas of type 1 diabetic rats.....................................................................21 Chapter 3. Results..............................................................28 3.1 Protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells.............................28 3.2 Effect of fenofibrate on adiponectin expression in retinas of type 1 diabetic rats.....................................................................32 Chapter 4. Discussion...........................................................38 4.1 Protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells.............................38 4.2 Effect of fenofibrate on adiponectin expression in retinas of type 1 diabetic rats.....................................................................43 Chapter 5. Conclusions and Prospects............................................50 5.1 Protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells.............................50 5.2 Effect of fenofibrate on adiponectin expression in retinas of type 1 diabetic rats.....................................................................53 Chapter 6. Summary..............................................................56 6.1 Protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells.............................56 6.2 Effect of fenofibrate on adiponectin expression in retinas of type 1 diabetic rats............................................................60 Chapter 7. References ..........................................................66 Chapter 8. Figures and Tables...................................................89 8.1 Figure contents........................................................89 8.2 Table contents........................................................113 Chapter 9. Appendix............................................................117 Figure Contents Figure 1. Clinical feature of diabetic retinopathy, including microaneurysm, microhemorrhage, cotton wool spots, neovascularization, and hard exudates...............................................................89 Figure 2. Mechanisms underlying hyperglycemia-induced oxidative stress increase that is involved in diabetic retinopathy pathogenesis.......................90 Figure 3. The effects of fenofibrate treatment on experimental models of diabetic retinopathy............................................................91 Figure 4. Model for regulation of ASK1-mediated apoptosis by Trx1 and Trx2.......92 Figure 5. Possible mechanisms for the improvement of glucose metabolism by adiponectin............................................................93 Figure 6. Cloning and functional analysis of adiponectin receptors...............94 Figure 7. Our hypothesis in the study “Protective of fenofibrate on oxidative tress-induced apoptosis in retinal-choroidal vascular endothelial cells”.................................................................95 Figure 8. Effects of fenofibrate on cell viability in paraquat (PQ)-stimulated RF/6A cells assessed using MTT assay.........................................96 Figure 9. Effects of fenofibrate on apoptosis in paraquat (PQ)-stimulated RF/6A cells assessed by flow cytometry.............................................97 Figure 10. Effects of fenofibrate on reactive oxygen species (ROS) production and oxidative stress indicators in paraquat (PQ)-stimulated RF/6A cells assessed by flow cytometry............................................98 Figure 11. Effects of fenofibrate on mitochondrial damage in RF/6A cells assessed by JC-1 staining.........................................................99 Figure 12. mRNA levels of peroxiredoxin (Prx), thioredoxin-1 (Trx-1), Trx-2, B-cell lymphoma 2 (Bcl-2), Bcl-xl, and B-cell lymphoma 2-associated X protein (Bax) in RF/6A cells detected using semi-quantitative PCR............100 Figure 13. Effects of fenofibrate on the expression of paraquat (PQ)-induced apoptosis and stress-signaling pathway-related proteins assessed by western blot analysis................................................101 Figure 14. Effects of fenofibrate on the expression of paraquat (PQ)-induced thioredoxins (Trxs), apoptosis signal-regulated kinase-1 (Ask-1), and cytochrome c assessed by western blot analysis.......................102 Figure 15. Effects of fenofibrate on the expression of paraquat (PQ)-induced apoptosis-related proteins assessed by western blot analysis.........103 Figure 16. The evaluation of mRNA levels of adiponectin, adipoR1, and adipoR2 in rat retinas by semi-quantitative PCR.................................104 Figure 17. The evaluation of protein expression levels of adiponectin, adipoR1, and adipoR2 in rat retinas by western blot analysis......................105 Figure 18. Quantification of the adiponectin levels in rat AqH and plasma using and ELISA................................................................106 Figure 19. Quantification of MCP-1 and IL-8 levels in rat AqH and plasma........107 Figure 20. Effects of fenofibrate on DM rat retinas as visualized by immunofluorescence staining of adiponectin, adipoR1, and adipoR......108 Figure 21. Evaluation of the protein expression levels of adiponectin, adipoR1, and adipoR2 in glucose-stimulated RGC-5 cells by western blot analysis...110 Figure 22. Evaluation of the protein expression levels of adiponectin, adipoR1, and adipoR2 in glucose-stimulated RAW264.7 cells by western blot analysis.. .....................................................................111 Figure 23. Evaluation of the expression levels of adiponectin, adipoR1, and adipoR2 in glucose-stimulated RF/6A cells by western blot analysis...........112 Table Contents Table 1. Major pharmacologic clinical trials of fenofibrate in diabetic retinopathy ........................................................................113 Table 2. Primer sequences for RT-PCR in the study “protective effect of finofibrate on oxidative stress-induced apoptosis in retinal/choroidal vascular endothelial cells......................................................114 Table 3. Primer sequences for RT-PCR in the study “effect of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats...................................................................115 Table 4. The body weight and blood sugar of animal experimental group...........116 | |
dc.language.iso | en | |
dc.title | 探討Fenofibrate對於治療糖尿病視網膜病變可能之機制 | zh_TW |
dc.title | Implication of Fenofibrate for Diabetic Retinopathy Treatment
| en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 楊偉勛(Wei-Shiung Yang) | |
dc.contributor.oralexamcommittee | 周祖述,何昭德,吳為吉 | |
dc.subject.keyword | 糖尿病視網膜病變,降血脂藥物fenofibrate,氧化壓力,細胞凋亡,第一型糖尿病大鼠模式,脂聯素, | zh_TW |
dc.subject.keyword | diabetic retinopathy,fenofibrate,oxidative stress,apoptosis,rat model of type 1 diabetes,adiponectin, | en |
dc.relation.page | 117 | |
dc.identifier.doi | 10.6342/NTU202100719 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-02-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1702202112194900.pdf 目前未授權公開取用 | 2.75 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。